Summary:
- This article discusses the development of a new COVID-19 vaccine candidate by researchers at the Weizmann Institute of Science in Israel. The vaccine is designed to target multiple variants of the SARS-CoV-2 virus, including the Omicron variant.
- The vaccine uses a novel approach called "multimeric nanoparticles" that can present multiple copies of the SARS-CoV-2 spike protein to the immune system, eliciting a stronger and more broad-ranging immune response.
- The researchers have successfully tested the vaccine in animal models and are now preparing to begin human clinical trials to evaluate its safety and effectiveness in protecting against COVID-19 infections caused by different variants of the virus.